Press Releases August 27, 2026 09:00 AM

Codexis to Participate in Cantor Global Healthcare Conference 2026

Codexis to Present at Cantor Global Healthcare Conference 2026 with Focus on Enzymatic Therapeutics Manufacturing

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CDXS

Codexis, Inc., a leader in enzymatic solutions for complex therapeutics manufacturing, announced its participation in the Cantor Global Healthcare Conference 2026. Management will engage in a fireside chat discussing their proprietary enzyme technologies and manufacturing platforms for advanced therapeutics, including RNAi drugs.

Codexis to Participate in Cantor Global Healthcare Conference 2026
CDXS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Codexis will participate in the Cantor Global Healthcare Conference 2026 and host a fireside chat to discuss its enzymatic solutions and manufacturing advancements.
  • The company leverages its proprietary CodeEvolver technology to develop high-performance enzymes for small molecule pharmaceuticals and nucleic acid synthesis.
  • Codexis is advancing its ECO Synthesis Manufacturing Platform to enable scalable enzymatic production of RNAi therapeutics, aiming to improve yields, reduce waste, and boost manufacturing efficiency.

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.

Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the event.

About Codexis

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, and greater sensitivity in genomic and diagnostic applications. For more information, visit  https://www.codexis.com.

For More Information

Investor Contact
Georgia Erbez
(650) 421-8100
[email protected]


Risks

  • Uncertainty exists regarding market adoption and commercial success of Codexis's proprietary enzymatic manufacturing platforms, which could impact revenue growth.
  • The development and scaling of enzymatic platforms for RNAi therapeutics manufacturing entail technical and regulatory risks that may affect timelines and costs.
  • Participation in investor conferences, while increasing visibility, doesn't guarantee investment or immediate positive stock performance amid competitive biotech and pharmaceutical sectors.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026